Hyper-Reflective Foci in Intermediate Age-Related Macular Degeneration: Spatial Abundance and Impact on Retinal Morphology.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
03 01 2023
03 01 2023
Historique:
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
1
2
2023
Statut:
ppublish
Résumé
The purpose of this study was to analyze spatially resolved structural changes at retinal locations in presence (+) or absence (-) of hyper-reflective foci (HRF) in eyes with subretinal pigment epithelium (RPE) drusen in intermediate age-related macular degeneration (iAMD). Patients with IAMD (n = 40; mean age = 69.7 ± 9.2 [SD] years) and healthy controls (n = 27; 64.2 ± 9.0) underwent spectral-domain optical-coherence-tomography imaging and fundus-controlled perimetry testing. After reviewing retinal layer segmentation, presence of HRF was annotated and retinal layer thicknesses (RLTs) extracted using ImageJ. Localized RLTs were compared between +HRF and -HRF positions. Univariate mixed linear models were used to investigate associations among RLT, HRF presence, and HRF size. In iAMD eyes, a mean of 11.1 ± 12.5 HRF were detected with a peak abundance at 0.5 to 1.5 mm eccentricity to the fovea. At +HRF positions, outer nuclear layer (ONL; P = 0.0013, average difference = -12.4 µm) and retinal pigment epithelium drusen complex (RPEDC; P < 0.0001, +45.6 µm) thicknesses differed significantly compared to -HRF positions, even after correcting for accompanying drusen-related RPEDC layer thickening (P = 0.01). Mixed linear models revealed a significant association between increasing HRF area and decreasing ONL (association score = -0.17, P < 0.0001; 95% confidence interval [CI] = -0.22 to -0.11), and inner photoreceptor segments (IS) layer thicknesses (-0.08, P = 0.005; 95% CI = -0.14 to -0.03). Spearman rank correlation analysis yielded a significant correlation between total HRF area and mesopic (P = 0.015), but not scotopic (P = 0.305) retinal sensitivity losses. Descriptive analysis of this study demonstrated a predominant distribution of HRF at a foveal eccentricity of 0.5 to 1.5 mm, whereas further refined topographic analysis revealed a significant ONL layer thinning in presence of HRF even after correction for sub-RPE drusen presence compared to lesions in absence of HRF. Longitudinal studies are further needed to analyze the prognostic impact as well as the role of HRF presence in the context of iAMD.
Identifiants
pubmed: 36705929
pii: 2785315
doi: 10.1167/iovs.64.1.20
pmc: PMC9896840
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Références
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3431-3439
pubmed: 30025092
Nat Rev Dis Primers. 2021 May 6;7(1):31
pubmed: 33958600
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1599-1608
pubmed: 29625486
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Invest Ophthalmol Vis Sci. 2015 Feb 10;56(3):1689-700
pubmed: 25670493
Ophthalmology. 2018 Feb;125(2):276-287
pubmed: 28964579
Ophthalmology. 2014 Aug;121(8):1572-8
pubmed: 24755005
JAMA Ophthalmol. 2020 Jul 1;138(7):740-747
pubmed: 32379287
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO211-BIO226
pubmed: 28785769
Ophthalmologica. 2018;239(2-3):110-120
pubmed: 29306951
Ophthalmology. 2017 Dec;124(12):1764-1777
pubmed: 28847641
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Eye (Lond). 2018 Dec;32(12):1819-1830
pubmed: 30068928
Ophthalmology. 2009 Mar;116(3):488-496.e2
pubmed: 19167082
Am J Ophthalmol. 2016 May;165:65-77
pubmed: 26940163
Ophthalmology. 2019 Dec;126(12):1667-1674
pubmed: 31281056
Invest Ophthalmol Vis Sci. 2012 Jul 09;53(8):4626-33
pubmed: 22589439
Ophthalmology. 2020 Mar;127(3):394-409
pubmed: 31708275
Ophthalmology. 2017 Dec;124(12):1753-1763
pubmed: 28712657
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Ophthalmology. 2015 Nov;122(11):2316-26
pubmed: 26298717
Ophthalmol Retina. 2021 Mar;5(3):241-250
pubmed: 32721592
Invest Ophthalmol Vis Sci. 2021 Aug 2;62(10):34
pubmed: 34448806
J Ophthalmol. 2021 Dec 17;2021:6096017
pubmed: 34956669
Lancet. 2018 Sep 29;392(10153):1147-1159
pubmed: 30303083
Ophthalmol Retina. 2021 Sep;5(9):855-867
pubmed: 33348085
Ophthalmology. 2009 May;116(5):914-20
pubmed: 19410950
Ophthalmology. 2013 Dec;120(12):2656-2665
pubmed: 23830761
Surv Ophthalmol. 2012 Sep;57(5):389-414
pubmed: 22898648
Ophthalmol Retina. 2020 Nov;4(11):1059-1068
pubmed: 32389889
Ophthalmology. 2011 Apr;118(4):687-93
pubmed: 21093923
JAMA Ophthalmol. 2020 Oct 1;138(10):1026-1034
pubmed: 32789526
Graefes Arch Clin Exp Ophthalmol. 2020 Nov;258(11):2353-2362
pubmed: 32666252
Ophthalmology. 2013 May;120(5):1038-45
pubmed: 23352193
Invest Ophthalmol Vis Sci. 2013 Mar 05;54(3):1603-12
pubmed: 23361506
Graefes Arch Clin Exp Ophthalmol. 2017 Aug;255(8):1551-1558
pubmed: 28534244
Am J Ophthalmol. 2020 Sep;217:162-173
pubmed: 32289293